Skip to main content


Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Mast cell depletion in the preclinical phase of collagen-induced arthritis reduces clinical outcome by lowering the inflammatory cytokine profile

Fig. 3

Absence of FcεRIβ+ cells during preclinical phase of CIA reduces clinical outcome of arthritis in effector phase of disease. a Progression of CIA was monitored by clinical scoring of RMB-DBA/1 mice, which have been injected with either PBS or DT in the preclinical phase of CIA (n = 15/group). b Serum levels of IgG1, IgG2a, IgG2c and IgE isotype antibodies directed against collagen type II were quantified in serum from PBS- or DT-injected RMB-DBA/1 mice (n = 15/group) (c) Mast cell numbers were determined in ankle joints of PBS- and DT-treated mice (n = 6/group). Arrows show mast cells in the joint. d Histological score of joint inflammation in the ankle joint of PBS- and DT-treated mice (n = 15/group). Representative H&E-stained sections of ankles obtained from PBS- and DT-treated RMB-DBA/1 mice. * p < 0.05. A representative example of two independent experiments is depicted. AUC area under the curve, DT diphtheria toxin, IgE immunoglobulin E, IgG immunoglobulin G, PBS phosphate-buffered saline

Back to article page